Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDUA | P35475 | 1/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15151 | 0.87 | IDUA (0.36) | IDUAGUSBCA1CA9PRKCA | |
| SCHEMBL15210146 | 0.87 | IDUA (0.36) | IDUAGUSBCA1CA9PRKCA | |
| Lactic Acid SCHEMBL7156907 | 0.81 | TP53 (0.34) | IDUAGUSBCA1CA9PRKCA | |
| SCHEMBL24602753 | 0.78 | CA1 (0.42) | CA1CA9PRKCATSHRCYP1A2 | |
| SCHEMBL5492523 | 0.78 | CA1 (0.42) | CA1CA9PRKCATSHRCYP1A2 | |
| SCHEMBL19284480 | 0.75 | PRKCA (0.45) | CA1CA9PRKCATSHRCYP1A2 | |
| SCHEMBL19297932 | 0.75 | PRKCA (0.45) | CA1CA9PRKCATSHRCYP1A2 | |
| SCHEMBL20045095 | 0.75 | — | — | |
| SCHEMBL20045087 | 0.75 | — | — | |
| SCHEMBL17831608 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0422765-A1 | Cosmetic composition | UNILEVER PLC (GB) | 1991-04-17 | — | — | EP | claimed |
| US-20210214298-A1 | DEOXYDEHYDRATION OF SUGAR DERIVATIVES | UNIV CALIFORNIA (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3333152-A1 | DEOXYDEHYDRATION OF SUGAR DERIVATIVES | The Regents of The University of California Santa Cruz (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017147098-A1 | DEOXYDEHYDRATION OF SUGAR DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-31 | — | — | WO | disclosed |
| EP-0422765-A1 | Cosmetic composition | UNILEVER PLC (GB) | 1991-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214298-A1 | DEOXYDEHYDRATION OF SUGAR DERIVATIVES | GCK, G6PD, SLC2A4 | IDUA 370/4885GUSB 618/4885CA1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.